Orgovyx
Term · Oncology and biomedicine · MLC-T-ONC-006150
A drug used to treat adults with advanced prostate cancer. Orgovyx binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, which blocks the pituitary gland from making the hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone. Orgovyx may stop the growth of cancer cells that need testosterone to grow. It is a type of GnRH antagonist. Also called relugolix.
| Identifier | MLC-T-ONC-006150 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | relugolix |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-006150",
"term": "Orgovyx",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with advanced prostate cancer. Orgovyx binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland, which blocks the pituitary gland from making the hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This causes the testicles to stop making testosterone. Orgovyx may stop the growth of cancer cells that need testosterone to grow. It is a type of GnRH antagonist. Also called relugolix.",
"synonyms": [
"relugolix"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/orgovyx/"
}
Record 12,345 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.